Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • 法伯氏病
Normal T1 Mapping Values Rule Out Adverse Cardiovascular Events in Fabry Cardiomyopathy: A New Multimodal Prognostic Score
Posted inCardiology news Radiology

Normal T1 Mapping Values Rule Out Adverse Cardiovascular Events in Fabry Cardiomyopathy: A New Multimodal Prognostic Score

Posted by MedXY By MedXY 01/05/2026
A prospective study of 167 Fabry disease patients identifies low T1 values, left ventricular hypertrophy, and late gadolinium enhancement as key predictors of major adverse cardiac events, leading to a robust new 3-year clinical prognostic score.
Read More
A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk
Posted inCardiology Nephrology news

A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk

Posted by MedXY By MedXY 01/05/2026
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
Read More
  • Precision Medicine Fails to Improve Postoperative Pain: Insights from the CYP2D6-Guided Opioid Trial
  • Albumin Replacement in Septic Shock: Safety Confirmed but Survival Benefit Remains Elusive
  • Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial
  • Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer
  • AAV9 Gene Therapy Shows Clinical Promise in Stabilizing Type II GM1 Gangliosidosis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in